Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 14, 2025 to May 14, 2025 Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Jan 2028 to Oct 10, 2028
    • Primary completion date changed from estimate of Jun 2026 to Jun 30, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 13 of 18 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are: * Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients? * Is the OFA protocol superior to the OA protocol? Participants will: * During anesthesia induction, the experimental group will receive remimazolam combined with esketamine for anesthesia, while the control group will receive remimazolam combined with remifentanil. * Record respiratory and circulatory indicators and adverse reaction times.
Trial Details
NCT Number NCT07002801
Lead Sponsor Harbin Medical University
Collaborators: First Affiliated Hospital of Harbin Medical University
Conditions
(from sponsor)		 Gastrointestinal Disease
Related terms Gastrointestinal Diseases
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov